• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Which patients for bisphosphonate control of breast cancer metastasis?

  • — 29 Mar, 2013
Rob Coleman
AudioMedica News
AudioMedica News
Which patients for bisphosphonate control of breast cancer metastasis?
Which patients for bisphosphonate control of breast cancer metastasis?
00:00 /
RSS Feed
Share
Link
Embed

ST GALLEN, SWITZERLAND—Bisphosphonates have an important part to play in managing breast cancer according to research reported at the 2013 St Gallen conference on “Primary Therapy of Early Breast Cancer”. Professor Robert Coleman, from Weston Park Hospital and the University of Sheffield in the UK told Peter Goodwin about findings from the AZURE study and from other research indicating that controlling bone turnover by using bisphosphonates can modulate the metastatic process favourably in post-menopausal women, but should not be used in younger women.



LISTEN

[audio:https://www.audiomedica.com/podcasting/oncology/130323RobertColemanPODCASTLoRes.mp3]

You may also like...

  • Chronic Lymphocytic Leukemia After Fludarabine Failure Chronic Lymphocytic Leukemia After Fludarabine Failure 26 Feb, 2008
  • Ayal Aizer Low risk prostate cancer: less treatment means lower cost, and better patient outcomes 16 Mar, 2013
  • ASCO Audio Journal of Oncology in Advance – June 15th, 2007 – reporting from: ASCO Annual Meeting, Chicago, June 1-5, 2007 ASCO Audio Journal of Oncology in Advance – June 15th, 2007 – reporting from: ASCO Annual Meeting, Chicago, June 1-5, 2007 16 Jun, 2007
  • Audio Journal of Prostate Cancer Special Edition 2005 Audio Journal of Prostate Cancer Special Edition 2005 14 Jan, 2006
  • Previous story Is breast cancer screening oversold?
  • Next story Dog walking cuts breast cancer recurrence risk
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic Lymphocytic…
    • Microbiome Diversity Key To Survival After Allogeneic…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • CT Screening Cuts Lung Cancer Deaths 24 Per Cent—Second…
    • New Front Line Standard for Older Patients with Chronic…
  • Home
  • Oncology
  • Which patients for bisphosphonate control of breast cancer metastasis?

© Copyright 2022 AudioMedica.com. Typegrid Theme by WPBandit.